Lobbying disclosures · Lobbying report
AMGN: second_quarter 2026 lobbying report
Issues related to visas Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Follow AMGN- Became public
- Jul 20, 2026, 11:17 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 8, 2026, 11:40 AM EST
Why this is connected
Exact legal-name match: AMGEN INC (https://www.sec.gov/Archives/edgar/data/318154/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/1ce4b9e9-92c8-4e50-8a27-ad73746318ca/","filing_uuid":"1ce4b9e9-92c8-4e50-8a27-ad73746318ca","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/1ce4b9e9-92c8-4e50-8a27-ad73746318ca/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey Miller","dt_posted":"2026-07-20T11:17:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"P.O. Box 625","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Buda","registrant_state":"TX","registrant_zip":"78610","registrant":{"id":401104313,"url":"https://lda.gov/api/v1/registrants/401104313/","house_registrant_id":null,"name":"MILLER STRATEGIES, LLC","description":"strategic public affairs","address_1":"P.O. Box 625","address_2":null,"address_3":null,"address_4":null,"city":"Buda","state":"TX","state_display":"Texas","zip":"78610","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEFFREY MILLER","contact_telephone":"+1 202-434-8242","dt_updated":"2026-07-30T15:40:39.312430-04:00"},"client":{"id":201397,"url":"https://lda.gov/api/v1/clients/201397/","client_id":354,"name":"AMGEN, INC.","general_description":"biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-01-01"},"lobbying_activities":[{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Issues related to visas","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in AMGN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 2, 2026$15K–$50K
Sen. Sheldon Whitehouse (D-RI)
$15K–$50K · Traded Oct 15, 2026 · disclosed Nov 2, 2026 · Spouse
Committee overlap: Finance - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 1, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 1, 2026
- Sep 5, 2026$1K–$15K
- Sep 5, 2026$1K–$15K
- Sep 2, 2026$1K–$15K
Sen. Sheldon Whitehouse (D-RI)
$1K–$15K · Traded Aug 12, 2026 · disclosed Sep 2, 2026 · Spouse
Committee overlap: Finance - Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 12, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
$1K–$15K · Traded Jun 5, 2026 · disclosed Jun 12, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.